Immunic, Inc. (IMUX) – What Are Brokerages Thinking About This Stock?

Shares of Immunic, Inc. (NASDAQ:IMUX) have received an average recommendation of “Buy” from the fourteen analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have issued a buy recommendation and four have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $35.43.

Several analysts have recently commented on IMUX shares. Zacks Research raised shares of Immunic from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Immunic in a report on Thursday, September 10th. Wall Street Zen lowered Immunic from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Roth Capital reissued a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, August 26th.

Institutional Investors Weigh In On Immunic

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its position in shares of Immunic by 21.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock worth $69,000 after buying an additional 1,400 shares during the period. CTC Alternative Strategies Ltd. purchased a new position in Immunic in the 1st quarter valued at approximately $27,000. ADAR1 Capital Management LLC purchased a new position in Immunic in the 1st quarter valued at approximately $33,000. Bank of America Corp DE grew its stake in shares of Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after acquiring an additional 143,689 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Immunic in the first quarter worth $187,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Price Performance

IMUX stock opened at $7.34 on Tuesday. The business has a 50 day simple moving average of $10.07 and a 200-day simple moving average of $11.46. The firm has a market capitalization of $100.12 million, a PE ratio of -1.68 and a beta of 1.45. Immunic has a 1 year low of $5.06 and a 1 year high of $17.43.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.36. On average, equities research analysts expect that Immunic will post -3.69 EPS for the current year.

Immunic Company Profile

Immunic, Inc (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies.

Immunic’s lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.